Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Retained Earnings (2018 - 2025)

Black Diamond Therapeutics' Retained Earnings history spans 6 years, with the latest figure at -$464.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 4.6% year-over-year to -$464.7 million; the TTM value through Dec 2025 reached -$464.7 million, up 4.6%, while the annual FY2025 figure was -$464.7 million, 4.6% up from the prior year.
  • Retained Earnings reached -$464.7 million in Q4 2025 per BDTX's latest filing, down from $142000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $335000.0 in Q1 2021 to a low of -$487.1 million in Q4 2024.
  • Average Retained Earnings over 3 years is -$147.7 million, with a median of -$25000.0 recorded in 2025.
  • The largest YoY upside for Retained Earnings was 100.53% in 2021 against a maximum downside of 127.99% in 2021.
  • A 3-year view of Retained Earnings shows it stood at -$218.0 million in 2021, then crashed by 123.49% to -$487.1 million in 2024, then grew by 4.6% to -$464.7 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Retained Earnings are -$464.7 million (Q4 2025), $142000.0 (Q3 2025), and -$25000.0 (Q2 2025).